Literature DB >> 3029239

Molecular epidemiology of live, attenuated varicella virus vaccine in children with leukemia and in normal adults.

L D Gelb, D E Dohner, A A Gershon, S P Steinberg, J L Waner, M Takahashi, P H Dennehy, A E Brown.   

Abstract

Restriction endonuclease analysis of varicella-zoster virus (VZV) DNA has been used in unraveling the complex epidemiology of VZV infections in individuals immunized with a live, attenuated varicella virus vaccine. Early rashes appearing within the first six weeks after vaccination are invariably due to vaccine virus. True breakthrough infections with wild-type VZV also occur in vaccinees. Five cases of zoster have been seen in leukemic children vaccinated while in remission. One case appeared 22 months after vaccination in the same general area as the inoculation. The virus isolated was vaccine derived. A second case of zoster appeared in a dermatome unrelated to the sites of vaccination approximately 19 months after apparently natural varicella. This virus was wild type. Vaccine virus can therefore establish latency and can later reactivate as herpes zoster.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3029239     DOI: 10.1093/infdis/155.4.633

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  8 in total

1.  Phylogenetic analysis of varicella-zoster virus: evidence of intercontinental spread of genotypes and recombination.

Authors:  Winsome Barrett Muir; Richard Nichols; Judith Breuer
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

2.  Comparison of the complete DNA sequences of the Oka varicella vaccine and its parental virus.

Authors:  Yasuyuki Gomi; Hiroki Sunamachi; Yasuko Mori; Kazuhiro Nagaike; Michiaki Takahashi; Koichi Yamanishi
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

3.  Molecular epidemiology of varicella-zoster virus in East London, England, between 1971 and 1995.

Authors:  K Hawrami; I J Hart; F Pereira; S Argent; B Bannister; B Bovill; D Carrington; M Ogilvie; S Rawstorne; Y Tryhorn; J Breuer
Journal:  J Clin Microbiol       Date:  1997-11       Impact factor: 5.948

Review 4.  Preventing varicella-zoster disease.

Authors:  Sophie Hambleton; Anne A Gershon
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

5.  Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild-type varicella-zoster virus isolates.

Authors:  P LaRussa; O Lungu; I Hardy; A Gershon; S P Steinberg; S Silverstein
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

6.  Analysis of enzymatic digestion pattern of two open reading frames of Varciella-Zoster genome from Kuwaiti patients using the RFLP technique.

Authors:  J A Qasem; M A Al-Fadhli; M A Saraya; J Thomas
Journal:  Iran J Microbiol       Date:  2012-12

7.  Prevention of shingles: safety and efficacy of live zoster vaccine.

Authors:  Dianna Quan; Randall J Cohrs; Ravi Mahalingam; Donald H Gilden
Journal:  Ther Clin Risk Manag       Date:  2007-08       Impact factor: 2.423

Review 8.  A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines.

Authors:  David B Huang; Jashin J Wu; Stephen K Tyring
Journal:  J Infect       Date:  2004-10       Impact factor: 6.072

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.